Yahoo Finance8d
Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Ovarian Cancer of Anti-HER2 Bispecific ADC JSKN003
JSKN003 is an anti-HER2 bispecific antibody-drug conjugate (bis-ADC), which is developed inhouse with Alphamab's proprietary Glycan-specific conjugation platform. JSKN003 can bind HER2 on the ...
Anti-HER2 Bispecific ADC JSKN003 Received Approval to Initiate a Phase III Clinical Study for the Treatment of HER2-positive Breast Cancer
Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has ...
Yahoo Finance16d
Anti-HER2 Bispecific ADC JSKN003 Received Approval to Initiate a Phase III Clinical Study for the Treatment of HER2-positive Breast Cancer
JSKN003 is an anti-HER2 bispecific ADC developed inhouse with Alphamab's proprietary Glycan-specific conjugation platform. The antibody molecule KN026 is site-specifically modified via enzyme ...
Radiance Biopharma Enters Exclusive License For ROR-1 Targeted Antibody Drug Conjugate
Under the terms of the Exclusive License, Radiance will pay CSPC an upfront payment of $15 million, and up to $150 million in potential development and regulatory milestone payments and over $1 ...
Nature12d
FDA approves TROP2-targeted antibody–drug conjugate for breast cancer
Alphamab is developing a bispecific ADC that targets both TROP2 and HER3. ModeX Therapeutics is meanwhile running a phase I trial of a tetraspecific T cell engager called MDX2001, which targets ...